Proprietary 4Degra resin technology spun out from leading UK universities with extensive IP
Differentiation
Value Proposition
Bioresorbable implants that gradually erode and are resorbed by metabolic processes as natural tissue regenerates
How They Differentiate
3D printable bioresorbable materials enabling customized patient-specific implants
Market & Competition
Target Customers
Orthopedic device manufacturers, medical implant companies, surgeons, hospitals
Industry Verticals
Medical Devices, Orthopedics, Soft Tissue Repair, Healthcare
Competitors
Traditional titanium implant manufacturers, Bioresorbable material companies
Growth & Milestones
Growth Metrics
ISO 13485 certified manufacturing (4D Biomaterials Ltd, Mar 2025); first product (bioabsorbable interference screw) in US FDA 510(k) pathway—still described as ongoing on company site as of 2026; Series B previously flagged as next raise
Major Milestones
Incorporated Oct 2018 / spun out Birmingham & Warwick Apr 2020; Innovate UK grant & pre-seed 2020; Series A £3.4M (Jul 2024, led Oshen Holdings); ISO 13485 for 4D Biomaterials Ltd (Mar 2025); second US patent US12275186B2 (Apr 2025); FDA 510(k) for bioabsorbable interference screw ongoing
4D Biomaterials is a UK-based developer of bioresorbable photopolymer resins for vat photopolymerization (VPP) 3D printing. The company's 4Degra material platform is designed to produce patient-specific implants that gradually degrade and are resorbed by the body as natural tissue regenerates, offering an alternative to permanent titanium implants in orthopedic and soft tissue repair.
The core technology is a proprietary resin formulation spun out from research at the Universities of Birmingham and Warwick. It enables the additive manufacture of porous scaffolds with controlled degradation rates, tailored to match healing timelines for different clinical applications. The company targets orthopedic device manufacturers and medical implant companies, with clinical testing underway involving leading surgeons.
4D Biomaterials positions itself as a first-mover in 3D printable bioresorbable orthopedic materials. Its differentiation lies in combining bioresorption with the geometric freedom of VPP printing, allowing custom implants that could reduce revision surgeries. The company has raised approximately £5 million from investors including Oshen Holdings, DSW Ventures, SFC Capital, and Boundary Capital, and is preparing for FDA clearance for its first orthopedic application.
A key open question is how the 4Degra platform's mechanical properties and degradation profiles compare to established bioresorbable polymers like PLLA or PLGA in load-bearing applications. Competing against both traditional titanium implant manufacturers and other bioresorbable material companies, 4D Biomaterials must demonstrate clinical and regulatory validation to secure adoption in the risk-averse medical device market.